MetaCap

Akebia Therapeutics (AKBA) vs Jyong Biotech (MENS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Akebia Therapeutics (AKBA) has outperformed Jyong Biotech (MENS) over the past year, losing 75.1% versus a loss of 95.3%. Jyong Biotech is the larger company by market cap ($110.2 million vs $107.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKBA-75.13%MENS-95.28%
+21%-40%-101%
Nov 21, 20251 yearNov 20, 2026
AKBA-89.52%MENS-81.90%
+760%+315%-130%
Jun 16, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKBA versus MENS key metrics
MetricAKBAMENS
Share price$0.3855$1.45
Market cap$107.04M$110.24M
1-day change-8.71%-17.14%
YTD return-76.06%-63.29%
1-year return-75.13%-95.28%
5-year return-85.56%—
EPS (TTM)$-0.17$-0.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$236.20M—
Revenue growth (YoY)+47.46%—
Net income (latest FY)$-5.34M$-4.67M
Gross margin83.29%—
Operating margin9.95%—
Net margin-2.26%—
52-week high$1.73$38.88
52-week low$0.361$1.43
Distance from 52-week high-77.72%-96.27%
Analyst consensusstrong_buy—
Avg. price target upside+678.21%—
Average volume8.05M44.23K
Shares outstanding277.66M74.23M
Employees19427
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AKBA has outperformed MENS by 20.2 percentage points over the past year.

About Akebia Therapeutics

AKBA stock →

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.

Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees

About Jyong Biotech

MENS stock →

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

AKBA vs MENS FAQ

Which is bigger, Akebia Therapeutics or Jyong Biotech?

Jyong Biotech (MENS) is larger, with a market capitalization of $110.24M compared with $107.04M for Akebia Therapeutics (AKBA).

Which stock has performed better over the past year, AKBA or MENS?

AKBA returned -75.13% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.

Are Akebia Therapeutics and Jyong Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons